Data integrity – Page 65

System access controls weak during system upgrade – risk-based ERES remediation

Addressing Weak System Access Controls During the System Upgrade: A Comprehensive Playbook In today’s pharmaceutical landscape, ensuring robust system access controls is paramount, especially during system upgrades. Weaknesses in these…

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – CAPA and revalidation strategy

Addressing Uncontrolled Hybrid Paper-Electronic Workflows During Inspection Walkthroughs In recent regulatory inspections, hybrid paper-electronic workflows have become a significant area of scrutiny. When not managed correctly, these workflows can lead…

Record retention failures during inspection walkthrough – 21 CFR Part 11 compliance gaps

Managing Record Retention Challenges During FDA/EMA/MHRA Inspections In today’s regulatory landscape, adherence to record retention requirements is non-negotiable, particularly under 21 CFR Part 11. Failures in maintaining accurate records can…

Record retention failures during inspection walkthrough – CAPA and revalidation strategy

Addressing Record Retention Failures During Inspection Walkthroughs: A Comprehensive CAPA and Revalidation Playbook In the highly regulated pharmaceutical environment, the integrity of record retention is pivotal for compliance during inspections.…

Record retention failures during validation lifecycle – 21 CFR Part 11 compliance gaps

Addressing Record Retention Failures in the Validation Lifecycle for Compliance In pharmaceutical manufacturing, ensuring robust compliance with regulatory frameworks is critical. Record retention failures are a significant concern during the…

Electronic signatures misused during system operation – risk-based ERES remediation

“`html Addressing Misuse of Electronic Signatures in System Operations: A Risk-Based Remediation Playbook The increasing reliance on electronic records and electronic signatures (ERES) in the pharmaceutical industry brings significant regulatory…

Hybrid paper-electronic workflows uncontrolled during system operation – inspection evidence requirements

Managing Uncontrolled Hybrid Paper-Electronic Workflows in Pharmaceutical Operations In today’s pharmaceutical landscape, integrating hybrid paper-electronic workflows has become a necessity. However, uncontrolled workflows during system operation can lead to significant…

Shared user credentials during laboratory walkthrough – 483 risk assessment

Risk Assessment for Shared User Credentials During Laboratory Walkthroughs In the pharmaceutical manufacturing sector, maintaining robust data integrity is critical to compliance with Good Distribution Practices (GDP) and the tenets…

Manual data transcription without verification during FDA inspection – 483 risk assessment

Assessing Risks of Manual Data Transcription Without Verification During FDA Inspections As pharmaceutical manufacturing and quality professionals, encountering challenges surrounding data integrity is not new. One of the significant issues…

Shared user credentials during internal audit – 483 risk assessment

Risk Assessment for Shared User Credentials During Internal Audits In today’s highly regulated pharmaceutical environment, the integrity of data and compliance with Good Manufacturing Practices (GMP) is paramount. The use…

Inadequate DI governance during system validation – CAPA effectiveness checks

Managing Inadequate Data Integrity Governance During System Validation: A Practical Playbook for Pharma Professionals In an era where regulatory scrutiny is intensifying, inadequate data integrity governance during system validation poses…

Repeat data integrity lapses during laboratory walkthrough – remediation roadmap regulators expect

Remediation Roadmap for Recurring Data Integrity Lapses Observed During Laboratory Walkthroughs Data integrity is pivotal in pharmaceutical manufacturing and laboratory settings, especially against the backdrop of increasing regulatory scrutiny. When…